Ablative decomposition, 193
Ablative device, 337
Ablative fractional photothermolysis (aFP)
clinical course, treatment, 140–141
photoaging improvement, 140, 142
tissue vaporization, 138–139
wound healing, 140
Ablative laser, children
indications and contraindications, 353
intra operative management, 355
preoperative management, 354–355
Acne and milia, 374
Acne scar, 337
Acne vulgaris
AAD, 187
blue light therapy, 189–190
components, 187
1,540 Er:glass laser, 189
inflammation reduction curve, 248
IPL, 190
KTP laser, 188
1,320 ND:YAG, 189
1,450-nm diode laser, 189
oxyhemoglobin, 188
\( P. \) acnes, 247
photodynamic therapy, 191
prevalence, 187
pulsed dye lasers, 188
red/blue light combinations therapy, 190
sebaceous glands, 188
treatment efficacy, 248, 249
Actinic keratosis (AK)
NMSCs, 246–247
non-pigmented lesions, 289, 291, 294
Adipose tissue
CO, laser, 199
focused ultrasound system, 199, 201
light and laser based treatments, 199, 200
liposuction, 201–202
Nd:YAG laser, 199
Age-related macular degeneration (ARMD), 440, 441
Alpha bisabolol, 361
American Academy of Dermatology (AAD)
acne, 187
ethical behavior, 379
governing bodies and professional organizations, 25
laser usage, 30–31
online resources, 410, 411
procedural skills, 27
American Medical Association (AMA), 379
American Osteopathic College of Dermatology (AOCD), 379
American Society for Aesthetic Plastic Surgery (ASAPS), 91, 388
American Society for Dermatologic Surgery (ASDS)
governing bodies and professional organizations, 25
procedural skills, 27
American Society for Laser Medicine
and Surgery (ASLMS), 25, 379, 411
American Society of Dermatologic Society, 383
American Society of Dermatologic Surgeons, 411
American Society of Dermatologic Surgery
(ASDS), 379
Aminolevulinic acid (ALA), 418
actinic keratoses treatment, 225–226
Aktilite device, 223
Blu-U device, 222
contraindications, 224
heme biosynthetic pathway, 221
MAL-PDT session, 222
PDT, 533, 534
photoaging, 224
porphyrin fluorescence and hematoxylin, 223, 224
porphyrins, 221
post-operative management, 226
pre-operative management, 225
prevention and treatment, 227
side effects/complications, 227
Androgenetic alopecia, 283
Anesthesia safety, 311, 312
Anesthesiology
airway
cor-morbidities, 599
dotracheal intubation, 600
indications and contraindications, 599
intermittent apnea technique, 600
post-operative management, 600
pre-operative management, 600
side effects/complications, 601–602
carbon dioxide lasers, 598
clinical research, 608
cutaneous and cosmetic laser surgery, 602–603
fiberoptics, laser, 599
laser beam, characteristics and sources, 598
laser safety program, 608–609
laser types, specific hazards, 609
medical instrument, 598
obstetrics and gynecology
bleeding and premature labor, 607
cionization, laser, 606, 607
feroscopic laser coagulation, 606
indications and contraindications, 606
Index

peroneal nerve injury, 607
pre-operative management, 606
pathologic process, 597–598
patient protection, 609
pediatrics
complications, 606
drug dosages, 605
indications and contraindications, 604
laryngospasm, 606
post-operative management, 605–606
pre-operative management, 604, 605
propofol infusion, 605
PWS, 605
protective eyewear, 609–610
radiographs, 598–599
retinal hazard region, 609
urology, 603–604
Antibiotic prophylaxis, 542
Anti-inflammatory agents, 361
Anti-vascular endothelial growth factors (anti-VEGF), 440
Anxiety disorder, 395
Argon fluoride (AFl) laser, 426
Argon laser
adverse events, 440
indications
cchoroidal neovascular membrane, 437–438
photocoagulation, focal, 437, 438
PRP, 436–437
technique
cchoroidal neovascular membrane, 440
photocoagulation, focal, 438–440
PRP, 438–439
uses, 440
Argon laser trabeculoplasty (ALT), 447
indications and contraindications, 453
side effects/complications, 454
techniques, 453, 454
Arnica montana, 371
Atrophic scar
ablative laser resurfacing, 49
definition, 48
fractional resurfacing, 49–50
nonablative laser resurfacing, 49	
tattoos, 315, 316, 318
B
Bare/urologic fibers, 546
Basal cell carcinoma (BCC), 289, 291–293
BDD. See Body dysmorphic disorder
Beam propagation
absorption coefficient, 11
cchromophores, 11
dermis and epidermis, 9
fluence attenuation, 10
laser light and biological tissue interaction, 9–10
light wavelength dependent optical penetration depth, 10
poikilodermatous, 10
skin optical properties, 9
Benign prostatic hyperplasia (BPH)
 complication, 566–567
HoLAP and HoLRP, 565
HoLEP, 565
holmium laser resection and enucleation, 566
indications and contraindications, 565–566
KTP laser, 564, 565
medical intervention, 564
optical penetration depths, 564
PVP, 564
treatment, 564, 565, 567
Best corrected visual acuity (BCVA), 431
Bipolar disorder, 392, 393
Bleeding, 466
Body dysmorphic disorder (BDD), 322
major depression, 390
preoccupations, 389
questionnaire, 390
repetitive behaviors, 389, 390
resources, 391
Body dysmorphic disorder questionnaire (BDDQ), 390
Bone ablation process, 475
Borderline personality disorder, 393–394
Bovine mucopolysaccharide-cartilage complex (MCC), 362
Bowen’s disease, 224–225
BPH. See Benign prostatic hyperplasia
Bruising, 326
C
Café au lait macules (CALMs), 70–71
Candela®, 346
Capacitance coupling, 541
Capillary malformations, port wine stains/nevus flammeus
alexandrite and Nd:YAG treatments, 37, 38
hypertrophic violaceous PWS, 37, 38
PDL treatment, adverse effect, 39
pink macular PWS, 37
PWS treatment, 36–37
Carbon dioxide (CO2) laser
ablation, tissue, 556
clinical and histologic benefits, 106
collagen fibers, 106
dissection and hemostasis, 545
Er:YAG laser, 107–109
gynecologic laparoscopic applications, 544
incision, excision and vaporization of tissues, 554–555
intermittent evacuation, 545
isotretinoin, 107
laser–tissue interaction, 108
modality, breast treatment, 556
Omniguide® fiber, 544
parameters, 542, 543
skin tone and wrinkle severity, 106, 107
waveguides, 544–545, 555
wavelength, 544
Cardiology and cardiothoracic surgery
acute myocardial infarction, 575
aorto-ostial lesions, 577
calcified lesions, 575–576
clinical complications, 580
clinical history, 573
clinical trials, 573
contraindications, 575
coronary allograft vasculopathy, 577–580
excimer laser, 573, 574
indications, cardiovascular medicine, 573, 574
left main disease, 575, 576
renal artery interventions, 580
saphenous vein grafts lesions, 577
stent restenosis, 577, 578
stroke, 580
thrombus, 575
TMLR, 577
total occlusions, 576–577
undilatable/uncrossable lesions, 575
venous system, 580
Cataract, 453
Cellulite
Alma Accent RF System, 204
FDA, 202
IPL, 202, 203
light emitting diode, 203
light sources and massage, 203
VelaSmooth™, 203, 204
Charge coupled device (CCD), 403
Children
ablative laser
indications and contraindications, 353–354
intra operative management, 355
preoperative management, 354–355
adverse events, 350–351
dermatologic condition, 345, 346
HOI, 348–349
KTP, 350
pediatric skin lesion, 355
pigmented lesion
café-au-lait macules, 352
CMN, 353
melanin and lentigines, 351
nevus spilus, 352
tattoos, 352–353
port wine stain
hemangioma, 347
post-treatment purpura, 346, 347
predictive factors, 347
trigeminal nerve, 348
vascular malformation, 346
quasi continuous laser, 350
vascular laser therapy, 349–350
vascular lesion, 345, 346
Choanal atresia, 513, 514
Choroidal neovascular membrane
adverse events, 440
indications, 437–438
technique and uses, 440
Chronic periodontal disease, 480
Clinically significant macular edema (CSME), 437
Closed-angle glaucoma (CAG), 448
Cochrane Database Systematic Reviews, 533
Cognitive-behavioral therapy (CBT), 390
Cold ablation, 193
Complementary metal oxide semiconductor (CMOS), 403
Confocal laser scanning microscopy (CM), 420
Congenital melanocytic nevi (CMN), 353
Contact dermatitis, 374
Contact/fiber optic method, 546
Corneal collagen cross-linking (CXL), 432
Corneal damage, 453
Corneal ectasia, 431
Corneal haze, 431
Corticoids, 361
Cryocautery, 526
Cryogen spray cooling (CSC), 341
Cutting technique, 553, 554
Cyclophocoagulation, 447
D
Dentistry
American Dental Laser, 464
anti-bacterial techniques
general pre-operative management, 481
indications and contraindications, 479–480
peri-implantitis treatment, 482, 483
periodontal pocket debridement, 481
post-operative management, 482–483
root canal decontamination, 481–482
side effects and complications, 483
continuous-wave emission mode, 464
erbium, chromium YSGG laser, 464
laser perceptions, 465
light dynamics, 465–466
LLLT
caries detection, 485
cosmetic resurfacing, 485
general pre-operative management, 487
indications and contraindications, 484
PAD, 485–486
photobiostimulation, 484
tooth whitening, 486
market penetration, 466
oral hard tissue
general pre-operative management, 474
indications and contraindications, 473–474
management, 474, 475
modification, 476–477
post-operative management, 478
side effects and complications, 478–479
surgical excision of bone, 477–478
tooth cavity preparation/caries removal, 475, 476
oral soft tissue
advantage, 469
general pre-operative management, 468
gingival tissue, upper left incisor, 469
gingival tissue, upper right incisor, 469, 470
immediate post-laser treatment, 469, 470
indications and contraindications, 466–467
laminate veneers/crowns, 468
pathological tissue resection, 470, 471
post-operative management, 470–471
restorative treatment, 3 months, 469, 470
side effects and complications, 471, 472
soft tissue management, 468, 469
trauma, 469
Dermal pigmented lesions
drug induced pigmentation, 74–75
melanocytic nevi, 72–73
melasma and post-inflammatory hyperpigmentation, 73–74
Nevus of Ota, 73
Dermatofibroma (DF), 293, 295
Derm Net website, 411
Dermatologic junction (DEJ), 133
Diabetic Retinopathy Study (DRS), 436
Diffuse lamellar keratitis, 432
Digital camera, 210
Digital nerve blocks, 333
Digital photography
advantages, 399
camera types
compact/subcompact, 400–401
SLR, 400
digital media, 403
equipment, 399, 400
flash, 402
image submission, publication, 404
imaging skill, 407
lenses
macro/close-up, 401–402
wide-angle zoom, 401
mega-pixel, 403
shooting techniques and tips
photographic technique, 405
pre and postoperative facial photography, 405–406
standard procedures, 404
surgical photography, 406
white balance, 402–403
Digital single-lens-reflex (DSLR), 400
Diode laser
adverse events, 443
indications, 441–442
technique, 442–443
uses, 444
1,450 nm Diode lasers, 169–170, 189
Diomed® laser, 549
Documentation consent. See Medicolegal issues
dorsal root entry zone (DREZ) lesions, 591
Dyspigmentation, 371–372
E
Early Treatment Diabetic Retinopathy Study (ETDRS), 436
Ecchymoses. See Bruising
Ectropion, 374
Edema, 369–370
Education, laser patient. See Laser patient
ELA-Max. See LMX–4 cream
eMedicine, 411
Endolaser
adverse events, 445
indications and techniques, 444
uses, 445
Endoscopic cyclophotocoagulation (ECP), 458, 459
Enoxolone, 361
Epidermal nevi (EN), 353
Epithelial defect, 431
1,540 nm Erbium glass laser, 170, 189
Erythema, 197, 369–370
Erythroxylon coca, 329
Ethical behavior
advertisement, 381
contraindications, 381
economics, 380
elective procedures, 379
interest, 380–381
physician and patient discussion, 380
training, 380
unethical conduct, 381
Ethnic skin
acne scar, 337
laser assisted hair reduction, 340
photorejuvenation
fractional device, 338
IPL and LED, 339
532 nm laser, 338
1,064 nm laser, 338–339
pre and post laser cooling, 341
skin tightening
infrared, 340
radiofrequency, 339
tattoos, 341
test spot, 342
vascular lesion, 340–341
Eutectic mixture of local anesthetics (EMLA) cream, 330, 354
Excited dimers, 193
External auditory canal (EAC), 507
Eyelid swelling, 326
Eye protection, 497
Eye safety
corneal eye shield
placement in adult, 310, 311
placement in child, 310
size, 309, 310
tray set up, 309
different wavelengths, 309
protection, eyewear types, 309
F
Facial nerve blocks, 333
Factitial dermatoses, 322
Flashlamp-pumped dye (FLPD) laser, 341. See also
Pulsed dye lasers
Fluorescence guided resection (FGR), 590
5-Fluorouracil (5-FU) therapy, 372, 373
Focal argon laser photocoagulation
adverse events, 440
indications, 437, 438
technique, 438–440
uses, 440
Food and Drug Administration (FDA), 425
hair reduction, 99
hair removal concept definition, 92
Fractional device
dermis, 19
first generation, 119
photorejuvenation, 338
photothermolysis, acne scar, 337
Fractional photothermolysis (FP), 315
adverse events and clinical pitfalls
antibiotic prophylaxis, 143, 144
bulk heat generation, tissue, 141
scarring effect, 142–143
aFP (see Ablative fractional photothermolysis)
average power, FP laser system, 127
bulk heating precaution procedure, 128
3-dimensional pattern, generation, MTZ, 126
home-use dermatology devices, 144–145
nFP (see Non-ablative fractional photothermolysis)
nFP and FP devices, 123, 125
pulse duration, 127
resurfacing modalities, 125–126
selective photothermolysis, 123–124
SMAS, 130
stamping and rolling technique, 127
thermal damage patterns, factors, 129
Frequency doubled double-pulse neodymium:
YAG (FREDDY) laser, 562
G
Generic laser hardware, 602
Glaucoma. See also Ophthalmology
clinical triad, 449
definition, 448
diagnosis, 447, 449
management, lasers, 450
medications, 447
multifactorial optic neuropathy, 448
OAGs and CAGs, 448
POAG, 448
Glottic carcinoma, 499
Glycyrrhetinic acid. See Enoxolone
Graphics interchange format (GIF), 404
Guide number (GN), 402
Gynecology
CO\(_2\) laser, 524
diathermia, 515
endometriosis, 524
HPV
classification, 524
incidence and prevalence, 524–525
risk factors, 524
tissue tropism and clinical infections, 525
myoma coagulation/myolysis, 523
vula, vagina, and cervix
cervical disease treatment, 527–528
diathermia, 515
endometrial ablation, 532
diathermia, 515
endometriosis and adhesiolysis, 533
indications and contraindications, 525–526
intracavitary and intra-abdominal laser procedure, 532
leiomyoma, 523–533
photodynamic therapy, 533–534
post-operative management, 530–531
preoperative management, 527
side effects/complications, 531–532
vaginal disease treatment, 528
vulvar disease treatment, 528–530

H
Hair growth
“biostimulation,” 281
LLLT, 280
Hairmax Lasercomb\textsuperscript{TM}, 282
helium neon laser, 282
mitochondrial transport chain, 281
mitochondria structure, 281
Sunetics\textsuperscript{®} International, 283
Hair removal
ASAPS, 91
FDA, 92
indications/contraindications, 92, 94
laser and intense pulsed light systems, 92, 93
“permanent hair reduction,” 92
prevention and treatment, 99
side effects/complications, 98–99
skin types, 99–100
superpulses, 92
techniques
intense pulsed light, 96–98
long-pulsed 755 nm alexandrite laser, 95
long-pulsed 694 nm ruby laser, 95
800 nm diode laser, 95–96
1,064 nm Nd:YAG laser, 96
nonpigmented hair, 98
post-operative management, 98
pre-operative management, 94
radiofrequency combinations, 98
TRT, 92
Hair transplantation
CO\(_2\) lasers
“biological glue,” 278
electrical hazard, 280
erbium laser, 279
laser recipient vs. steel created sites, 278, 279
pathology, 279
risk inherence, 279
FDA approval, 280
follicular unit transplantation, 277
International Society of Hair Restoration Surgery, 278
laser applications, 278
pros and cons, 280
Heat generation
LTI molecular basis, 13–14
SPT
extreme localized heating, 11–12
Q switched Nd YAG laser, 12
thermal relaxation time, 12–13
Heating, reaction types and effects
photochemical effects
biostimulation, 16
excimer laser, 16
luminescence, definition, 15
photodisruption/photodecomposition, 16
photodynamic reactions, 16
plasma induced ablation, 16–17
PpIX fluorescence, 16
photomechanical effects, 15
photothermal effects, 14–15
Hemangiomas of infancy (HOI), 348–349
Hemorrhoidectomy, 556
Hereditary hemorrhagic telangiectasias (HHT), 513, 514
Herpes simplex virus (HSV), 374
Histronic personality disorder, 394
Holmium laser enucleation of the prostate (HoLEP), 565
Holmium laser resection of the prostate (HoLRP), 565
Holmium laser vaporization of the prostate (HoLAP), 565
Human immunodeficiency virus (HIV), 367
Human papilloma virus (HPV), 367
classification, 524
incidence and prevalence, 524–525
risk factors, 524
tissue tropism and clinical infections, 525
Hyaluronic acid, 362
Hydroquinone, 363
Hyperthermia, 590
Hypertrichosis, 373
Hypertrophic scar, 315–318
Hyphema, 453
Hypopharyngeal carcinoma, 499
Hypopigmentation, 314, 316. See also Vitiligo
Infantile hemangioma, 316–318
Infectious keratitis, 432
Infiltrative anesthesia
anesthetic agents, 331, 332
bupivacaine and etidocaine, 331
diabetic nerve block, 332–333
non-ablative rejuvenation, 332
pigmented lesions and hair removal, 331–332
tattoos, 331–332
tumescent anesthesia, 332
Inflammatory linear verrucous epidermal nevus
(HLVEN), 353
Infantile hemangioma, 316–318
Informed consent. See Medicolegal issues
Infrarhoid epiglottic cancers, 499
Infrared tightening, 340
Institutional board review (IRB), 381
Intense pulse light (IPL)
adverse reactions, 217
benign vascular lesions
  hemangiomas, 211, 212
  POC, 211–212
  PWS, 212–213
reticular leg veins, 209–210
telangiectasias, 210–211
device for acne, 190
hair removal, 216
indications, 209
leg vein treatment, 58–59
non-ablative photorejuvenation
  botulinum A, 215
  lumenis, 214, 215
murine model, 214
photodynamic therapy, 215
sun exposure, UV damage, 213
non-coherent filtered flash lamp, 207
photorejuvenation, 339
photothermolysis, 207, 217
pigmented lesions, 213
scars, 215–216
sources, 112–113, 171, 172
spot size, 208
vascular treatment, 36
wavelength and pulse duration, 208
Interface debris, 431
Internet website
  expansive source, 412
medical resources, 409
quality evaluation, 409–410
Intra-axial brain tumors, 589–590
Intralase®, 426
Intralesional corticosteroids and 5-FU, 48, 50
Intradural tumors, 588
Intraocular pressure (IOP). See Ophthalmology
Intrinsic signal optical imaging (ISOI), 586
Investigational Device Exemption (IDE), 381

J
Journal of American Academy of Dermatology (JAAD), 381, 411

K
Keloid scar, 315–318
KTP laser. See Potassium titanyl phosphate laser

L
Laparoscopic cholecystectomy, 540
Laryngeal mask airway (LMA), 312
Laser-assisted subepithelial keratectomy (LASEK), 425
Laser assisted vascular anastomosis, 588–589
Laser discectomy, 588
Laser Eustachian tuboplasty (LETP), 507
Laser injury, laparoscopic surgery, 550–551
Laser in-situ keratomileusis (LASIK)
  ablation and reshaping, 426
  excimer laser, 427, 428
  femtosecond laser unit, 426, 427
  flap folds, 428
  microkeratomes, 426
  stromal hydration, 427
  wave-front guided, 428–430
Laser iridotomy
  alternate route for aqueous, 450
complaints, 453
definition, 447
indications and contraindications, 451
post-operative management, 452
pre-operative management, 451–452
q-switched Nd:YAG and the argon laser, 452
side effects, 452
surgical iridectomies, 450
Laser parameters, 543, 544, 552
Laser patient
color, 326
delegating procedure, 323
education
  adverse event, 327
  bruising, 326
  counseling, 323–325
downtime, 327
  erosion, 326
  hives and blisters, 326–327
laser treatment, 325
  presenting complaints, 323
procedure-related problems, 327
redness and swelling, 326
selection
  body dysmorphic disorder, 322
dissatisfied patient, 322
  problem identification, 322, 323
procedure, performance, 323
psychiatric illness and factitial dermatoses, 322
reasonable patient finding, 321
tanned, 326
Laser peripheral iridoplasty, 447
Laser practice
  common mistake, 415
delegate and nondelegate procedures, 415
device cost, 414
evidence based device integration, 413–414
energy based device integration, 413–414
evidence based review, 414
laser/light treatment, 415
marking, 414–415
peer review, 414
rent vs. lease vs. purchase, 414
Laser retractors, 553
Laser safety. See also Anesthesia safety; Eye safety
  administrative controls, 27–28
anesthesia, 497
ASLMS, 25
eye and skin protection, 28–29
  governing bodies and professional organizations, 25–26
  laser-specific endotracheal tube, 496, 497
laser usage
  ASDS and AAD, 30–31
  Board of Medicine, 31
  state regulation, 31
  Texas Board, 32
non-beam hazards, 29–30
  patient, surgeon and surgical staff, 496
  procedural skills, 26–27
  protective equipment, 28
  protocol, 497
warming signs and labels, 28
Laser safety eyewear (LSE), 609, 610
Lasers and lights, pigmented lesions treatment
  CALMs, 70–71
dermal pigmented lesions (see Dermal pigmented lesions)
epidemiology, 64
epidermal lesions, 71, 72
epidermal pigmented lesions, 69
highly pigment selective lasers, 67–69
laser-tissue interactions (see Laser-tissue interactions, pigmented skin)
lentigines, 70
pigment nonselective lasers, 66–67
prevention and treatment, 79
Q-switched and pulsed lasers and light sources, 65–66
ruby laser radiation, 64
side effects/complications, 78–79
techniques
anesthesia, 76
patient evaluation, 75–76
pigmented lesion, 77
post-operative management, 78
Q-switched laser, 77
safety measures, 76–77
“suntans,” 78

Laser surgery
anesthesia
adverse effects, 333, 334
classification and mechanism, 329, 330
conscious sedation, 334
Erythroxylon coca, 329
evolution, 329
infiltrative anesthesia (see Infiltrative anesthesia)
lidocaine, 329
novacaine, 329
pediatric patients, 334
pregnancy, 334
topical anesthesia, 330–331
fractionated treatment, 417–418
history, 417
in vivo optical microscopy, 420–421
LLLT, 419–420
photodynamic therapy, 418–419
PTB, 418
1.319/1.320 nm Laser systems, 167–169

Laser-tissue interactions
beam profiles, top hat vs. Gaussian, 6
dermis compact
carbonization, 20
hyperosmolar solutions, 20
optical properties change, real-time, 19–20
photon recycling, 20
photothermal responses, 20–21
polarizing lamp, 21
scatter limited therapy, 21
selective cell targeting, 21
spot diameter, 19
laser beam
focus, 17–18
target vacuum, 18
light, 1–2
light device
CO₂ lasers, 5
erbium YAG lasers, 5
laser tissue interactions, 4
light sources, 3
Q-switched alexandrite laser, 5
total light dose (fluence), 4
types, 2–4
optical damping, 19
photothermal-photochemical conversion, 17, 18
pigmented skin
epidermal melanocytes activation, 65, 66
melanin biosynthesis, 64–65
melanin, oxyhemoglobin and water, 64–65
Q-switched ruby laser irradiation, 65, 66
pixilated injury, 18–19
pulse profiles, square vs. spiky, 6
radiofrequency (RF) technology
beam propagation (see Beam propagation)
electrode deployment, 9
heat conduction, chromophore, 17
heat generation (see Heat generation)
reaction types and effects
(see Heating, reaction types and effects)
“synergy,” 9
wavelength ranges
absorption coefficients, 6, 7
cutaneous surgery, 6
far infrared systems, 8–9
MIR-lasers and deeply penetrating halogen lamps, 8
near IR (II), 7–8
red and near IR (I), 7
user controllable temperature change, IPL, 7

Laser trabeculoplasty, 447, 450
ALT, 454
biologic theory, 454
indications and contraindications, 455
mechanical theory, 454
patient position, slit lamp-mounted laser, 455, 456
post-operative management, 456
pre-operative management, 455
repopulation theory, 454
side effects/complications, 456–457
SLT, 454
LASIK. See Laser in-situ keratomileusis

Leg veins
argon lasers, 54
cavitation, 56
classifications, 53
clinical endpoints, 59
complications, 60
contraindications, 55
diode lasers, 57
epidermal cooling techniques, 56
erythematous dermatitis, 54
indications, 55
IPL, 58–59
KTP laser, 56
long pulsed dye laser, 56
long pulsed 755 nm alexandrite laser, 56–57
Nd:YAG lasers, 55, 57–58
oxyhemoglobin, 55
postoperative results, 59
sclerotherapy, 60
varicose and spider veins, 53
Zimmer air-cooling device, 60

Leukotrichia, 373
Light-emitting diode (LED), 339
definition, 232
dome-type LED, 232, 234
vs. lasers/IPLs, 232, 235
light production, 232, 233
phototherapy
acne vulgaris, 247–249
applications, 260
clinical efficacy, 245
‘colorology,’ 261
continuous wave, 262
contraindications, 257–258
dose recommendation, 262
eye protection, 256
FDA, 261
history, 231–232
incident power density, 263
intensity, definition, 261–262
light-tissue interaction (see Light-tissue interaction)
‘NASA LED,’ 258
NASA technology, 261
new wavelength discovery, 258–259
NMSCs and actinic keratosis, 246–247
Omnilux® revive™, 261
‘on-board’ chips, 259
optical hazards, 256–257
PAT, 245
PDT (see Photodynamic therapy)
peer-reviewed literature/peer-reviewed journals, 263
‘photobath,’ 259
photon intensities, 259
platelet-rich plasma (PRP), 256
psoriasis, 255
safe handling guidelines, 256
side effects, 257
skin rejuvenation (see Skin rejuvenation)
‘toy’ systems, 245–246
‘white papers,’ 246
wound healing (see Wound healing)
substrates and colours, 232, 234
usage
flashlamp, 234
flat panel arrays, 235
laser and IPL, 232
‘set-it-and-forget-it’ microprocessor-controlled technology, 236
Light gated ion channels, 592–593
Light-tissue interaction
beam, temporal profile, 242–243
dosimetry
bioeffects, 241
energy density (ED), 240, 241
photothermal damage, 242
Grotthus-Draper Law, 236
membrane-located transport mechanisms, 239
optical density (OD), 236
oxyhemoglobin absorption curve, 237
photon density (PD)
Arndt-Schultz law, 240
bioeffects, 239, 240
definition, 239
LED array, 240, 241
photon intensity, 236
photoreception, 239
photospectrogram, 237, 238
photothermal and athermal reactions, 236–238
photothermolysis, 237
Propionibacterium acnes, 238
Lipomas, 588
Liposuction
external ultrasound, 201–202
internal ultrasound, 202
635 nm laser, 201
1,064 nm laser, 201
Liquefied fat, 553, 554
LLLT. See Low level laser therapy
LMX–4 cream, 330–331
Low level laser therapy (LLLT), 280
caries detection, 485
composite resin curing, 485
general pre-operative management, 487
Hairmax Lasercomb™, 282
helium neon laser, 282
indications and contraindications, 484
mitochondrial transport chain, 281
mitochondria structure, 281
PAD, 485–486
photobiomodulation, 556, 557
reported effects, clinical dentistry, 484
stimulatory effects, 484
Sunetics® International, 283
tooth whitening, 486
Low level light therapy, 419–420
Macular Photocoagulation Study (MPS), 438
Medicolegal issues
clinical outcome, 384–385
informed consent elements, 384
laser therapy, 384
nonverbal protocol function, 383
patient and physician objectives, 383
pediatric patient, 384
quality assurance, 385
Melanocytic lesions
dysplastic nevi, 297
dermal papillae, 298, 301
dermoscopic and RCM mosaic image, 298, 301
epidermal and symmetrical architecture, 298
melanocytic nests, 300, 301
lentigo simplex, 297–299
malignant melanoma, 297–298
atypical cobblestone pattern, 300, 303
cellular-level resolution, 300
cerebriform nests, 303
dermo-epidermal junction, 300
epidermis and dermis, 300, 302
follicular aperture and dendrites, 300, 304
“melanin dust,” 300
non nucleated cells, 300, 304
pigmented melanomas, 300, 302
pleomorphic cells, 303
RCM, disadvantage, 304
RCM features, 301
melanocytic nevi, 297–299
Meningiomas, 589
Menorrhagia, 532
Methylaminolevulinate (MAL)
Aktilite device, 223
BCC treatment, 226
contraindications, 224
MAL-PDT session, 223
non-melanoma skin cancer, 222
porphyrin fluorescence and hematoxylin, 223, 224
post-operative management, 226
pre-operative management, 225
prevention and treatment, 226
side effects/complications, 226
Minimally invasive surgery
argon laser, 545–546
CO2 laser
dissection and hemostasis, 545
gynecologic laparoscopic applications, 544
intermittent evacuation, 545
OmniGuide® fiber, 544
parameters, 542, 543
waveguides, 544–545
wavelength, 544
“conventional” devices, 549, 550
diode laser technology, 548–549
fiber capable lasers, 543
holmium laser, 548
KTP laser
laserscope, 547
parameters, 542, 543
persistent bleeding, 548
pure lime green light, 547
wavelength, 547, 548
laparoscopic surgery, 542, 543
vaporization, tumors, 547
wavelength, 546
trocar placement, 550
Monoamine oxidase inhibitors (MAO) inhibitors, 392
Mood disorder
bipolar disorder, 392
major depression, 391–392
Moses effect, 548
Mucopolysaccharide-cartilage complex (MCC), 362
Multiphoton microscopy (MPM), 420
Mycosis fungoides (MF), 289, 291, 293
N
Narcissistic personality disorder, 394
National Institute of Health (NIH), 411
1,064 nm Nd:YAG lasers, 166–168
Neodymium:yttrium-aluminum-garnet (Nd:YAG) laser, 35
energy, 546
1,320 nm length, 189
parameters, 542, 544
sculpted fibers, 547
vaporization, tumors, 547
wavelength, 546
trocar placement, 550
Neurology and neurosurgery
ISOI, 586, 587
neurophotonics, 583–584
neurotherapeutic applications
cerebrovascular, 588–589
neuroendoscopic and pediatric applications, 591
neuro-ontologic, 589–590
peripheral nerve applications, 591
spinal, 588
stereotactic and functional, 590–591
NIRS and photon migration
Beer’s law technique, 585
diffusion process, 585
elastic scattering, 584
frequency domain, 585
molar extinction coefficients, 584
noninvasive monitoring, chromophores, 584
time domain, 585–586
OCT, 586–588
optical technologies
neural control, 592–593
spatial domain imaging, 591, 592
Nominal Hazard Zone (NHZ), 28
Non-ablative fractional photothermolysis (nFP)
DEJ, 133
dermal remodeling, 132–133
energy dependent response, 133–134
MEND, definition, 132
MTZs depth and diameter, 130–131
photoaging treatment, 136–137
pigment removal, MENDs shuttle process, 132–133
PIH, 134–135
scarring, clinical improvement, 138
skin histology, nFP device, 131
skin histology, nFP treatment, 131–132
small blood vessels coagulation, 133
thulium laser, 135–136
Non-ablative laser skin resurfacing
device, radiofrequency, 117
1,450 nm diode laser, 115–116
1,540 nm erbium:glass laser, 116–117
indications and contraindications, 111
IPL source, 112–113
1,320 nm Nd:YAG laser, 114–115
PDL, 112–113
postoperative management, 117
preoperative management, 112
prevention and treatment, 117
1,064 nm Q-switched Nd:YAG laser, 113–114
side effects/complications, 117
Non-invasive rejuvenation/skin tightening
dyschromias, 175
limiting factors, 175
1,064 Nm Nd:YAG laser, 184–185
skin laxity, deep stratum photoaging
animal hide contraction, 181–184
deep reticular dermis, 181
“flashlamps,” 181
skin contraction, 181–183
“stamping technique,” 182
trans-cooling and post cooling pulse, 181
skin strata, 175
superficial stratum, 185
Titan and 5 Nd:YAG, 175, 180
Titan, 3 Nd:YAG and 5 IPL, 175, 180
Titan 3 Nd:YAG laser, 175, 178–179
Titan treatment, 175–178
Non-melanoma skin cancers (NMSCs), 246–247
Normal-mode ruby laser (NMRL), 73
Novacaine, 329
O
Obsessive–compulsive personality disorder (OCPD), 394–395
Ocular damage, 367
Online resources
expansive source, 412
medical resources, 409
patient websites, 411–412
physicians websites, 410–411
quality evaluation, 409, 410
Open-angle glaucoma (OAG), 448
Open surgical procedures, 551–552
Operative site and surgical retractors, 552–553
Ophthalmology. See also Visual refraction
ALT (see Argon laser trabeculoplasty)
anterior segment anatomy and physiology, 448
aqueous humor, 448
argon laser (see Argon laser)
CAG, pupillary block, 448, 449
clinical treatment, 449–450
cycloidalysis clefs, 458
cyclophotocoagulation, 457–459
diagnosis, 449
diode laser
adverse events, 443
indications, 441–442
technique, 424–443
uses, 444
endolaser, vitreoretinal surgery
adverse events, 445
indications and techniques, 444
uses, 445
endoscopic cyclophotocoagulation, 458, 459
glaucoma, 450
goniophotocoagulation, 458
goniopuncture, 458, 459
iridotomy
alternate route for aqueous, 450
complications, 453
indications and contraindications, 451
post-operative management, 452
pre-operative management, 451–452
q-switched Nd:YAG and the argon laser, 452
side effects, 452
surgical iridectomies, 450
laser sclerostomy, 458
laser trabeculoplasty, 454–457
OAG, 448, 449
PDT
adverse events, 441
indications, 440–442
technique and uses, 441
pharmacotherapy, 445
posterior segment applications, 435–436
subconjunctival sutures cut, 458
symptoms, 449
xenon arc photocoagulator treatment, 435
Optical coherence tomography (OCT), 421, 440
imaging, visualization, and quantification capabilities, 588
reflection method, 586–587
spectral domain system, 586, 587
three-dimensional information, 587
Optical penetration depth (OPD)
MTZ, 135
nFP lasers, 127
in water, lasers, 126
Oral hard tissue
general pre-operative management, 474
indications and contraindications, 473–474
management, 474, 475
modification, 476–477
post-operative management, 478
side effects and complications, 478–479
surgical excision of bone, 477–478
tooth cavity preparation/caries removal, 475, 476
Oral soft tissue
advantage, 469
general pre-operative management, 468
gingival tissue, upper left incisor, 469
gingival tissue, upper right incisor, 469, 470
immediate post-laser treatment, 469, 470
indications and contraindications, 466–467
laminate veneers/crowns, 468
pathological tissue resection, 470, 471
post-operative management, 470–471
restorative treatment, 3 months, 469, 470
side effects and complications, 471, 472
soft tissue management, 468, 469
trauma, 469
Otolaryngology
argon laser, 496
CO₂ lasers, 495
giant pulse laser/Q-switching, 495
historical aspects, 495
holmium:YAG and erbium:YAG laser, 496
KTP(Nd:YAG) laser, 495
laryngology
complications, 505, 506
devices, 503
endoscopic examination, 498
glottic carcinoma, 503–504
hemangiomas and vascular malformations, 500–501
hypopharyngeal carcinoma, 504
laryngomalacia, 501, 504–505
larynx anatomy, 502
malignancy, 499–500
micromanipulator coupled surgical laser, 498
papillomas, 500, 504, 505
polyps, 500
post-operative management, 505–506
pre-operative management, 502
Reinke’s edema, 501
safety, 506
Steiner’s work, 498
supraglottic carcinoma, 504
suspension laryngoscopy, 502, 503
TLM, 501
vocal cord paralysis, 501, 505
laser safety
anesthesia, 497
laser-specific endotracheal tube, 496, 497
patient, surgeon and surgical staff, 496
protocol, 497
oropharyngeal
indications and contraindications, 510–511
PDT, 512
post-operative management, 512
pre-operative management, 511
RF ablation, 511
side effects/complications, 512
T1 and T2 oral tumors, 512
T1 and T2 oral tumors, 511
otology
applications, 510
audiometric analysis, 508
cholesteatoma, 507, 508
conductive hearing loss, 507
Eustachian tube dysfunction, 507
myringotomy, 508
otosclerosis, 507
post-operative management, 509–510
pre-operative management and laser selection, 507–508
side effects/complications, 510
stapedectomy, 507–509
stapedotomy, 507
treatment, EAC, 507
tympanoplasty, 508–509
tympanostomy, 508
pediatric otolaryngology
choanal atresia, 514–515
congenital subglottic stenosis, 515
laryngomalacia, 515, 516
laser myringotomy, 517
pre- and post-operative management, 516
side effects/complications, 517
subglottic hemangioma, 515, 516
subglottic stenosis, 515
vallecular cyst, 515
rhinology, 513–514

P
Pain, 369
Palliative therapy, 499–500
Pan-retinal photocoagulation (PRP)
  adverse events, 440
  indications, 436–437
  technique, 438–439
  uses, 440
Papilloma, 599
Para-aminobenzoic acid (PABA), 331
Paradoxical tattoo darkening, 375
Pars plana vitrectomy (PPV), 440
PDL. See Pulsed dye lasers
Penetrating keratoplasty (PKP), 432
Percutaneous laser disc decompression (PLDD), 548
Personality disorders
  borderline, 393–394
  clusters, 392–393
  histrionic, 394
  narcissistic, 394
  obsessive–compulsive, 394–395
Photo-activated disinfection (PAD), 485–486
Photobiomodulation, 556–557
Photobiostimulation. See Low level laser therapy
Photochemical tissue bonding (PTB), 418
Photoderm™, 207
Photodisruption, 427
Photodynamic therapy (PDT)
  acne vulgaris, 228
  actinic keratoses, 221
  adverse events, 441
  ALA (see Aminolevulinic acid)
  basal cell carcinoma, 221
  BPH, 567
  endogenous PDT, 244–245
  exogenous PDT, 243–244
  gynecology, 533–534
  indications, 440–442
  MAL (see Methylaminolevulinate)
  neurology and neurosurgery, 590
  otolaryngology, 512
  photosensitizer/photosensitizer precursor, 221
  research issues, 418–419
  technique and uses, 441
Photoepilation, 373
Photoimmunotargeting (PIT), 419
Photokeratomeisis (PKM), 425
Photon absorption therapy (PAT), 245
Photorefractive keratectomy (PRK), 425
Photorejuvenation, 338–339, 417
Photoselective vaporization of the prostate (PVP), 565
Photosensitizers (PS), 418, 419
Photothermal laser nerve stimulation, 592
Pigmented lesions, 373–374
Pigmented non-melanocytic lesions
  DF, 293, 295
  pigmented basal cell carcinoma, 293, 295
  pigmented mammary Paget disease, 293, 295, 297
  seborrheic keratosis, 293, 295–297
Pituitary tumors, 589
Plasma resurfacing. See Plasma skin regeneration
Plasma skin regeneration (PSR)
  basal cell layer, 151
  clinical improvements, 153, 154
  coblation, 153
  CO₂ lasers, 156
  EMLA cream, 154
  epidermis vaporization, 149
  eyelid laxity and periorbital rhytides, 154
  FDA, 160
  finite element analysis, 151, 152
  Fitzpatrick skin types I–IV, 151
  Gaussian distribution, 150
  indications and contraindications, 154–155
  “lunch hour” procedure, 149
  nonablative resurfacing, 160
  Portrait® PSR system, 150, 153
  postoperative management
    desquamation, 158
    facial rhytides, 156, 159
    healing time, high energy treatment, 156
    healing time, low energy PSR1 treatment, 156, 157
    periorbital rhytides, 156, 158
    petrolatum-based ointment, 156
    postoperative erythema, 156
    preoperative management, 155
  prevention and treatment, 159
  pulse energy effects, 151, 152
  relative downtime vs. resurfacing modalities, 153, 154
  side effects/complications, 159
  single and double pass procedures, 155
  skin tightening and textural improvement, 159
  thermal effects, 151
  treatment protocols, 151–153
  turquoise blue non-contact target ring, 155
Plateau iris, 453
Platelet-derived growth factors (PDGF), 45
Pojikoderma of Civatte (POC), 211–212
Port-wine stain (PWS)
  anesthesiology, 605
  children
    post-treatment purpura, 346, 347
    predictive factors, 347
    trigeminal nerve, 348
    vascular malformation, 346
  IPL, 212–213
  Post inflammatory hyperpigmentation (PIH), 134–135
  Post-resurfacing leucoderma and striae, 194
Potassium titanyl phosphate (KTP) laser
  acne, 188
  laserscope, 547
  laser treatment, children, 350
  leg vein treatment, 56
  parameters, 542, 543
  persistent bleeding, 548
  pure lime green light, 547
  wavelength, 547, 548
Power density, 542
Presumed ocular histoplasmosis syndrome (POHS), 438, 441
Prevention and treatment, laser complications
  commonly used lasers, 364
  cooling, 366–367
  crusting and vesiculation, 370
  dermatologic laser therapy, 365, 368
  dyspigmentation, 371–372
erythema and edema, 369–370
laser mechanics, 366
operating room, safety, 367
pain, 369
patient factor, 368
photoepilation, 373
pigmented lesions, 373–374
professional error, 367–368
purpura, 370, 371
resurfacing, 374–375
scarring, 372–373
tattoos, 375
vascular lesions, 375

Primary open-angle glaucoma (POAG), 448
Procaine. See Novocaine
Proliferative diabetic retinopathy (PDR), 436
Protoporphyrin IX (PpIX), 419
Psoriasis
excimer lasers, 193–194
Fitzpatrick skin type, first dose determination, 196
indications and contraindications, 195, 196
molecular pathogenesis, 198
risks and benefits, 196
subsequent dose determination, 196
PSR. See Plasma skin regeneration
Psychiatric illness, 322
Psychological condition
anxiety disorder, 395
BDD (see Body dysmorphic disorder)
body image dissatisfaction, 387, 388
evaluation factors, 389
mood disorder
bipolar disorder, 392, 393
major depression, 391–392
patient evaluation, 388, 389
personality disorders
borderline, 393–394
clusters, 392–393
histrionic, 394
narcissistic, 394
obsessive–compulsive, 394–395
psychological complication, 388, 396
PubMed, 411
Pulsed dye lasers (PDLs)
acne, 188
anesthesia safety, 311, 312
definition, 366
disadvantage, 165
duct stone management, 555
hypertrophic scars and keloidal lesion treatment, 165
purpura, 166
rejuvenation, 166, 167
resurfacing, 112–113
selective photothermolysis, 165
skin biopsies, 165
sub-surfacing, 164
treatment, vascular, 35
type III procollagen, 166
vascular lesions, 341
Punctate inner choroidopathy (PIC), 441
Purpura, 370–371
Q
Q-switched laser, 166, 167
1,064 nm Q-switched neodymium:YAG laser, 113–114
Quantitative light-induced fluorescence (QLF), 485
Quasi continuous laser, 350

R
Radio frequency (RF), 339
Reactive oxygen species (ROS), 418
Reasonable expectations patients, 321
Reflectance-mode confocal microscopy (RCM)
aneucleated polygonal corneocytes, 288–289
applications
biopsy guide, 305
dermoscopy-RCM correlation, 304–305
margin assessment and surgery
adjunct, 305, 306
treatment response, 305, 306
dermis, 288
epidermis, 288
history, 286
in vivo imaging, advantages, 286
limitations and potential solutions, 306–307
non-invasive imaging techniques, 286
non-pigmented lesions
AK, 289, 291, 294
BCC, 289, 291–293
MF, 289, 291, 293
oral cavity neoplasm, 289, 293
SCC, 289, 291, 295
skin neoplasm, 291
normal skin, objective lens, 289, 290
pigmented lesions
melanocytic lesions (see Melanocytic lesions)
pigmented non-melanocytic lesions
(see Pigmented non-melanocytic lesions)
principles
laser light, 286
melanin, 287
optical fibre, 287
pinhole resolution, 287
skin movement, 288
Resurfacing
ablative laser skin resurfacing
CO₂ laser (see Carbon dioxide laser)
indications and contraindications, 104–105
postinflammatory hyperpigmentation, 110–111
postoperative management, 109
preoperative management, 105–106
prevention and treatment, 109–110
side effects and complications, 109, 110
fractional laser technology, 120
fractional photothermolysis, 118–119
non-ablative laser skin resurfacing
1,450 nm diode laser, 115–116
1,540 nm erbium:glass laser, 116–117
indications and contraindications, 111
IPL source, 112–113
1,320 nm Nd:YAG laser, 114–115
PDL, 112–113
postoperative management, 117
preoperative management, 112
prevention and treatment, 117
1,064 nm Q-switched Nd:YAG laser, 113–114
radiofrequency device, 117
side effects/complications, 117
procedures history, 103–104
Reticulate erythema, 373
Retinoic acid, 363
Returns on investment (ROI), 413
Risk, benefit and alternatives (RBA), 383, 384
S
Safety, See also Eye safety; Laser safety; Laser-tissue interactions
anesthesia (see Anesthesia safety)
corneal eye shield
placement in adult, 310, 311
placement in child, 310
size, 309, 310
tray set up, 309
hair protection
surgical lubricant, eyebrows, 310, 312
surgical lubricant, eyelashes, 310, 312
tongue depressor, 310, 312
Sapphire tip technology, 547
Scars, 372–373
category, etiology, 315
hypertrophic, keloid and atrophic ablative lasers, 315
baseline and melasma, 316, 320
cogulation, 316
erthema, thickness and pruritus, 315
hemangioma, 316–318
hypopigmentation and textural change, 316, 318
non-ablative fractional erbium treatments, 316, 317
resolution, atrophic scar, 316, 319
ruby laser treatments, 316, 317
skin type II, moderate acne scarring, 316, 319
indications and contraindications, 46–47
techniques
ablative laser resurfacing, 49
fractional resurfacing, 49–50
intralosomal corticosteroid, 48
nonablative laser resurfacing, 49
post-operative management, 48
pre-operative management, 47–48
wound healing process, hypertrophic scars, 45–46
Seasonal affective disorder (SAD), 391
Selective laser trabecuoplasty (SLT), 447
Selective photothermolysis (SPT)
extreme localized heating, 11–12
Q switched Nd YAG laser, 12
thermal relaxation time, 12–13
Selective serotonin reuptake inhibitors (SSRIs), 390
Silicone gel, 363
Silicone ointment, 362
Single lens reflex (SLR), 400
Skin laxity, deep stratum photoaging
animal hide contraction, 181–184
deep reticular dermis, 181
“flashlamps,” 181
skin contraction, 181–183
“stamping technique,” 182
trans-cooling and post cooling pulse, 181
Skin protection, 497
Skin rejuvenation
5-ALA, 250
extracellular matrix (ECM), 248
fractionated/fractional technology, 249
IR/red light, 250, 251
nonablative resurfacing, 249
Skin’s stratum corneum, 330
Smoke evacuation, 497
SmoothBeam laser, 169
Spatial frequency domain imaging (SFDI) system, 585, 586
Squalene oil, 362
Squamous cell carcinoma (SCC)
non-pigmented lesions, 289, 291, 295
oropharyngeal, 510, 512
Stall out phenomenon, 478
Sub-surfacing lasers
ablative laser resurfacing systems, 162
adverse events, 172
classifications, 161, 164
erthema, 162, 163
IPL sources, 171, 172
mid-infrared lasers
1,450 nm diode lasers, 169–170
1,540 nm erbium glass laser, 170
1,319/1,320 nm laser systems, 167–169
1,064 nm Nd:YAG lasers, 166–168
Q-switched laser, 166, 167
pigmentary dyschromias and vascular change, 163
post-treatment hypopigmentation, 162, 163
vascular lasers
KTP lasers, 164, 165
PDL (see Pulsed dye lasers)
Superficial musculoaponeurotic system (SMAS), 130
Supraglottic carcinoma, 499
T
Tagged image file format (TIFF), 404
Tattoo
allergenicity, 84–85
carbon dioxide lasers, 86
definition, 83
dermatologic uses, lasers, 86
freedom–2 ink technology, 89
historical perspectives, 83–84
ink color, tattoo removal, 88
Q-switched alexandrite laser, 87
Q-switched Nd:YAG laser, 87
removal, laser treatment, 85–86
amateur and multicolor, 313
complications, 314, 316
cosmetic, 313–314
dark skin types, 314, 315
scarring, 313
ruby laser, Q-switched, 87
tattooing techniques, 84
Tetracaine gel, 331
Textural change, 372
Thermal relaxation time (TRT), 92, 207, 208, 366
Thulium fiber laser, 567
Time domain photon migration, 585–586
Time-resolved spectroscopy (TRS), See
Time domain photon migration
Tissue cooling effects, 133
Tissue splatter and pinpoint bleeding, 373–374
Transforming growth factor Beta (TGF-β), 45
Trans myocardial laser revascularization (TMLR), 577
Transoral laryngeal microsurgery, 499
Transoral laser microsurgery (TLM), 501, 503
large granulomas formation, 506
tracheotomy post operation, 506
Transpupillary thermotherapy (ITT), 443
Transurethral resection of the prostate (TURP) syndrome, 603, 604
Triamcinolone (TAC), 50, 373
U
Ultraviolet-A light (UVA), 432
Urology
BPH
complication, 566–567
HoLAP and HoLRP, 565
HoLEP, 565
Holmium laser resection and enucleation, 566
indications and contraindications, 565–566
KTP laser, 564, 565
medical intervention, 564
optical penetration depths, 564
PVP, 564
treatment, 564, 565, 567
laser lithotripsy
adverse event, 563
coumarin laser, 562
erbium laser, 564
fiber development, 563, 564
holmium laser, 562, 563
indications and contraindications, 562, 563
ruby laser, 561–562
technical specifications, 562
laser-tissue interaction mechanism, 561, 562
strictures
erbium:YAG laser, 568
Ho:YAG laser, 568–569
indications/contraindications, 568
laser tissue welding techniques, 569
laser urethrotomy/ureterotomy, 568
types, 567
ureteral and urethral strictures, 568
Urticarial-like plaque, 373
Uvulopalatopharyngoplasty (UPPP), 510–511
V
Vascular lesions
alexandrite laser, 35
combination pdl and Nd:YAG laser, 36
epidermal temperature control, 34
ethnic skin, 340–341
frequency-doubled Nd:YAG, 35
IPL, 36
laser treatment options
capillary malformations (see Capillary
malformations, port wine stains/nevus flammeus)
hemangiomas, 39
spider angiomas, 39–40
telangiectasias, 40–41
vascular anomalies, 41–42
venous lakes, 41–42
non-coherent pulsed light devices, 33, 34
PDL, 35
pulse duration, 34
reticulated purpura, 375
selective photothermolysis, 33–34
Verrucae vulgaris (VV), 350
Vestibular schwannomas, 589
Virgin angioma, 324
Visual refraction
complications
anatomic, 430–431
healing/infection/inflammation, 431–432
refractive, 431
CXL, 432
surface ablation
advantage, 426
LASEK, 426
LASIK (see Laser in-situ keratomileusis)
PRK, 425, 426
Vitamin C, 363
Vitiligo
erthema, 197
excimer lasers, 194
first dose determination, 197
grafting techniques, 198
indications and contraindications, 195
subsequent dose determination, 197
Vitreoretinal surgery. See Endolaser
Vulvar intraepithelial neoplasia (VIN), 534
W
Water-based gel filters, 207
Wave-front guided LASIK
ablation vs. risk of keratectasia, 430
ocular aberrations, 428
WaveScan®, 428, 429
WaveScan®, 428, 429
Wildberry extract and kojic acid, 363
Wound dressing/care
ablative laser, 359
cosmetic effects, 363
laser procedure, 359
postoperative treatment
(0–48 h), 360–361
(1–2 week), 362
(3–4 week), 362
(72 h to 1 week), 362
(greater than 4 week), 362–363
(please insert greater than symbol)
schedule and indications, 360
topical agents (“open” technique), 360
scarring, 363
thermal injury, 359
Wound healing
acute wounds, 267
vs. chronic ulcers, 269
dye-enhanced tissue welding, 270
growth factors, 270
laser-assisted tissue bonding, 269, 271
lasers vs. conventional methods, 270–271
laser systems and parameters, optimal wound
bonding, 272
tissue soldering, 270
tissue welding, 269–270
chronic wounds, 273
advantages, 274
Ca influx and mitosis rate, 272
low intensity laser therapy, 274
United States, 267
cutaneous wound healing phases, 267
laser-assisted wound healing, 274
“laser welding,” 269
light wavelength
‘biostimulation,’ 252
cytochrome-c oxidase, 253
dermal and epidermal cell, action potentials, 253, 254
Er:YAG laser ablation, 255
facial electric spark burn injury, 254
HeNe laser, 252
mesenchymal cell, 255
‘quasi-wounding,’ 254
PAT, 250
process phases, 251
stages, 251–252
tissue repair
classification, 267
inflammatory phase, 268
proliferative phase, 268–269
remodeling phase, 269
Z
Zenker’s diverticulum, 511